Learn more about Signatera and the foundational technology that is transforming care for patients with cancer. Hear directly from Natera CEO Steve Chapman on how Signatera can detect molecular residual disease and help determine whether therapy is working. #CancerCare

It’s a time to celebrate life, share hope, and recognize the incredible strength of those living with and beyond cancer. Whether you’re reflecting on your own survivorship or standing beside a loved one, today is about connection, resilience, and community. At Natera, we’re

We’re pleased to announce that our genome-based Signatera MRD assay is now covered by Medicare. This coverage applies to patients with colorectal, breast, bladder, ovarian, and lung cancers, as well as those receiving pan-cancer immunotherapy monitoring—extending access across a

Later this month, Natera celebrates five years since opening lab operations in Austin. In those five years, our Austin team has delivered critical insights that support timely, informed decisions for patients and clinicians around the world. Behind every test is a team of

💙💚

Proud moment: The VANISH study shows Panorama identifies the viable twin in a vanishing twin pregnancy with 100% accuracy. ow.ly/1gpL30sNCBq #Panorama #VanishingTwin #PrenatalTesting

Excited to celebrate #Natera’s 10 year listing anniversary this morning at the Nasdaq opening bell 🔔

Watch Natera CEO Steve Chapman on Squawk Box as he shares insights on the molecular residual disease (MRD) landscape and how Signatera is helping transform care for cancer patients. cnbc.com/video/2025/07/…

Our CEO Steve Chapman underscores the growing role of renal genetic testing in helping clinicians deliver earlier, more personalized care. When we better understand a patient’s genetic risk, we can intervene sooner and change the course of disease. #ThePowerOfKnowing

Congratulations to Michael Brophy, #Natera’s CFO, on being named Best CFO in the public company category by the Austin Business Journal. Since joining Natera in 2015, Mike has played a critical role in guiding the company’s financial strategy, helping achieve cash flow breakeven in 2024 and

We look forward to connecting at #WTC2025 in San Francisco, August 2 - 6. Join us for special events highlighting the latest in transplant innovation, including a tour of our local #Natera lab. RSVP: ow.ly/AKMq50WsQkq #Natera #TransplantCare @astschimera @ast_info TTS

💙💚 This #WorldIVFDay & #WorldEmbryologistDay we celebrate the experts who help families grow. Thank you for your work and the crucial role you play in shaping the future of reproductive health. ow.ly/HSVa50WvmrO #Natera

Our CEO, Steve Chapman, recently had the honor of ringing the opening bell on Nasdaq to celebrate our 10th anniversary as a public company. As part of the bell-ringing ceremony, Steve spoke about when and how Natera was founded — and how the company has evolved since then. We

We are proud to collaborate with the Austrian Breast & Colorectal Cancer Study Group (ABCSG) on the launch of the TEODOR clinical trial. TEODOR is a Phase II randomized controlled trial using Signatera to identify patients with breast cancer for de-escalation of

We had an incredible week at WTC 2025! 🔬 16 abstracts across kidney, heart and lung, including 5 oral presentations 📊 Featured the latest data on Prospera for organ transplant assessment 🎤 Standing room only at our symposium with leading voices in transplant medicine Thank

Today marks a proud moment for Naterans and an important advancement for patients with muscle invasive bladder cancer. Together with our collaborators, we announced positive topline results from the Imvigor011 clinical trial. The study showed that Signatera™-positive patients

Natera is continuing to collaborate on important trials in muscle-invasive bladder cancer. Most recently, we announced that Signatera was selected for the randomized, phase III ARCHER trial, which is sponsored by NRG Oncology through National Cancer Institute's Clinical Trials Network. ARCHER aims to

Today is #TealDay for ovarian cancer awareness and Team Natera dressed in teal to show their support! Our partner is National Ovarian Cancer Coalition, an incredible resource for statistics, support, and more to empower your healthcare journey. 💙💚 Learn more:

Insightful look into trial enrollment, CKD diagnosis and more in renal genetics from Dr. Ronen Schneider, Medical Director of Renal Genetics at #Natera. 🎧 ow.ly/Tozm30sQ3AY

Amanda was diagnosed with stage IV CRC at 36. Now in survivorship, she uses Signatera™ for post-op surveillance to help manage recurrence risk. With CRC rising in people under 50, earlier detection and informed care matter more than ever. ow.ly/e6SI30sU1Ae #CRCMonth